MAGEA4 and neoplasm: Afami-cel (or ADP-A2M4) therapy was studied in a phase I multi-tumor trial aimed at evaluating safety and clinical activity of afami-cel in HLA-A*02+ patients with advanced metastatic MAGE-A4-expressing solid tumors across nine tumor types, including SyS (NCT03132922).